Scoping the needs and gaps of onchocerciasis endemic countries in the context of the NTD road map 2021-2030

Report of the sixth meeting of the WHO Onchocerciasis Technical Advisory Subgroup: virtual meeting, 19-21 December 2022

Endectocide and ectocide products for malaria transmission control: preferred product characteristics

WHO Malaria Policy Advisory Group (MPAG) meeting report, 18–20 April 2023

WHO Onchocerciasis Technical Advisory Subgroup: report of the seventh meeting, Saly, Senegal, 4 November 2023

Results of the 2022 global WHO online survey on diagnostic capacities and treatment practices for implantation (deep) mycoses

WHO Malaria Policy Advisory Group (MPAG) meeting report, 30 October–1 November 2023

WHO guideline on preventive chemotherapy for public health control of strongyloidiasis

WHO Malaria Policy Advisory Group: meeting report, 8-10 April 2025

Elimination of kala-azar as a public health problem in South-East Asia: template dossier

Master protocol for surveillance of pfhrp2/3 deletions and biobanking to support future research

Diagnostic tests for detecting risk of Plasmodium vivax relapse: preferred product characteristics

Harmonizing diagnostic polymerase chain reaction procedures for skin-related neglected tropical diseases: meeting report, Madrid, Spain, 8-10 July 2024

Sixteenth meeting of the Strategic and Technical Advisory Group for Neglected Tropical Diseases: hybrid meeting, 27-28 September 2022

Vector control products targeting outdoor malaria transmission: preferred product characteristics

Report of the third meeting of the WHO Onchocerciasis Technical Advisory Subgroup, Geneva, Switzerland, 26-28 February 2019

Indoor residual surface treatments for malaria transmission control in areas with insecticide-resistant mosquito populations: preferred product characteristics

Assessing schistosomiasis and soil-transmitted helminthiases control programmes: monitoring and evaluation framework

Global report on neglected tropical diseases 2024

Early detection and management of neurological serious adverse events in relation to the administration of anthelminthic medicines to people with asymptomatic neurocysticercosis